Patent · US Active

Biomarkers of response to proteasome inhibitors

US9920373B2 · kind B2 · utility

0Cited by

0References

18Claims

0Family size

Assignee

Millennium Pharmaceuticals, Inc. · US

Inventors

Allison Berger · Arlington, US
Nibedita Chattopadhyay · Wellesley, US
Erik M. Koenig · Cambridge, US

Key dates

Filing date	Nov 9, 2012
Grant date	Mar 20, 2018
Priority date	—
Expiry date	Jul 19, 2033

Classification

Technology area (CPC C)Chemistry; Metallurgy
CPC primaryC12Q2600/158
WIPO fieldPharmaceuticals
WIPO sectorChemistry

Abstract

Disclosed are markers associated with sensitivity to treatment with proteasome inhibitors. Sensitivity is observed when RAS gene is wild type in tumor cells. Compositions and methods are further provided to assess markers of marker genes to predict outcome of treatment using proteasome inhibitors to patients having a solid tumor, such as a lung tumor or a colon tumor.

Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.